Spots Global Cancer Trial Database for Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Official Title: A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose
Study ID: NCT05394103
Study Description
Brief Summary: Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic, Phoenix, Arizona, United States
University of Southern California, Los Angeles, California, United States
Mayo Clinic, Jacksonville, Florida, United States
Northwestern University, Chicago, Illinois, United States
Mayo Clinic, Rochester, Minnesota, United States
Atlantic Health System Hospital, Morristown, New Jersey, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
Asan Medical Center, Seoul, , Korea, Republic of
Severance Hospital, Seoul, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
